<DOC>
	<DOCNO>NCT01652469</DOCNO>
	<brief_summary>Using laboratory test ( VeriStrat ) , patient relapse squamous cell lung cancer assign two stratum , VSG ( VeriStrat Good ) VSP ( VeriStrat Poor ) . They randomize EGFR-TK inhibitor ( erlotinib ) chemotherapy ( Docetaxel ) . It hypothesize VeriStrat test result able predict benefit treatment erlotinib v docetaxel . This would suggest significant improvement progression-free survival VSG patient treat Erlotinib , significant improvement VSP patient receive treatment .</brief_summary>
	<brief_title>Testing Drugs Erlotinib Docetaxel Lung Cancer Patients Classified Regarding Their Outlook Using VeriStrat® .</brief_title>
	<detailed_description>Goals study : 1 . Explore predictive ability VeriStrat signature , test interaction treatment arm ( Arm A : erlotinib v Arm B : docetaxel ) VeriStrat status ( VSG v VSP ) use outcome progression free survival . 2 . Explore whether treatment erlotinib provide progression free survival benefit compare docetaxel VSG group . 3 . Compare progression free survival two treatment arm ( Arm A : erlotinib v Arm B : docetaxel ) VSP group . 4 . Explore prognostic ability VeriStrat signature test overall difference progression free survival two VeriStrat group ( case significant interaction ) . 5 . Explore predictive ability VeriStrat signature use secondary measure clinical efficacy include overall survival , objective response rate , disease control rate . 6 . Compare overall survival , objective response rate disease control rate treatment group separately VSG VSP group . 7 . Explore prognostic ability VeriStrat signature test overall difference overall survival , objective response rate disease control rate two VeriStrat group ( case significant interaction ) . 8 . Assess safety tolerability two treatment separately VeriStrat group overall . Recruitment period : 18 month Sample Size : 500</detailed_description>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>Histologically cytologically confirm locally advanced stage IIIB , amenable radical radiotherapy , metastatic stage IV nonsmall cell lung cancer ( NSCLC ) predominant squamous subtype , accord 7th edition TNM classification , include M1a ( separate tumor nodule contralateral lobe , tumor pleural nodule malignant pleural pericardial effusion ) and/or M1b ( distant metastasis ) . Progressive disease upon previous chemotherapy include least one line platinumbased chemotherapy . Measurable evaluable disease accord RECIST v1.1 ( Appendix 2 ) . ECOG PS 02 . Age ≥ 18 year . Adequate organ function , include : Adequate bone marrow reserve : ANC &gt; 1.5 x 109/L , platelet &gt; 100 x 109/L . Hepatic : bilirubin &lt; 1.5 x ULN ; AP , ALT &lt; 3.0 x ULN ; AP , ALT &lt; 5 x ULN acceptable case liver metastasis . Renal : calculated creatinine clearance &gt; 40 ml/min base Cockroft Gault formula . Signed date informed consent form . Male female patient reproductive potential must use approved contraceptive method , trial 12 month thereafter . Female patient reproductive potential must negative pregnancy test within 7 day prior study registration . Estimated life expectancy &gt; 12 week . Patient compliance geographical proximity allow adequate followup . Evidence medical condition would impair ability patient participate trial might preclude therapy trial drug ( e.g . unstable uncompensated respiratory , cardiac , hepatic renal disease , active infection , uncontrolled diabetes mellitus ) . Previous treatment EGFRTKI docetaxel . Documented brain metastasis unless patient complete local therapy central nervous system metastases corticosteroid least 14 day prior study registration . Documented presence activate EGFR mutation , patient test EGFR mutation . Previous malignancy within past 5 year exception adequately treat cervical carcinoma situ , breast cancer situ localize nonmelanoma skin cancer . Psychiatric disorder preclude understanding information trial related topic , give informed consent , interfere compliance oral drug intake . Concurrent treatment experimental drug anticancer therapy treatment clinical trial within 21 day prior study registration . Known hypersensitivity trial drug hypersensitivity component trial drug concomitant drug contraindicate .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>squamous cell</keyword>
	<keyword>NSCLC</keyword>
	<keyword>TKI</keyword>
	<keyword>Erlotinib</keyword>
	<keyword>Docetaxel</keyword>
	<keyword>VeriStrat</keyword>
	<keyword>protein signature</keyword>
</DOC>